Patents by Inventor Alan Verkman
Alan Verkman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210095006Abstract: This disclosure provides the use of recombinant IgG Fc multimers for the treatment of neuromyelitis optica (NMO), and methods of treating NMO by administering such multimers.Type: ApplicationFiled: December 14, 2018Publication date: April 1, 2021Inventors: Rolf SPIRIG, Adriana BAZ MORELLI, Alan VERKMAN, Lukmanee TRADTRANTIP
-
Publication number: 20120101143Abstract: The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., DF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.Type: ApplicationFiled: April 15, 2011Publication date: April 26, 2012Inventors: Alan Verkman, R. Kiplin Guy, Nicoletta Pedemonte, Luis J.V. Galietta
-
Patent number: 8143295Abstract: The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ?F508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquino-line-containing compounds of the invention, or an analog or derivative thereof.Type: GrantFiled: March 8, 2006Date of Patent: March 27, 2012Assignee: The Regents of the University of CaliforniaInventors: Alan Verkman, Nicoletta Pedemonte, Luis J. V. Galietta
-
Patent number: 8129365Abstract: The invention provides chromoionophore compounds comprising a triazacryptand (TAC) K+ ionophore conjugated to at least a first chromophoric moiety (e.g., xanthylium dyes and derivatives thereof). In related embodiments, the chromoionophore compounds further comprise a second chromophoric moiety which is insensitive to potassium binding by the TAC ionophore, thus providing for dual wavelength detection and absolute determination of K+ concentration. The invention further provides methods and kits for the determination of K+ concentrations in biological systems, either in vitro or in vivo, using embodiments of inventive chromoionophores.Type: GrantFiled: October 11, 2006Date of Patent: March 6, 2012Assignee: The Regents of the University of CaliforniaInventors: Alan Verkman, Prashant A. Padmawar
-
Patent number: 8058295Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound.Type: GrantFiled: November 19, 2009Date of Patent: November 15, 2011Assignee: The Regents of the University of CaliforniaInventors: Alan Verkman, Tonghui Ma
-
Publication number: 20110119775Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound.Type: ApplicationFiled: January 21, 2011Publication date: May 19, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Alan Verkman, Nitin Dattatraya Sonawane, Chatchai Muanprasat
-
Patent number: 7939558Abstract: The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., ?F508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.Type: GrantFiled: June 2, 2005Date of Patent: May 10, 2011Assignee: The Regents of the University of CaliforniaInventors: Alan Verkman, R. Kiplin Guy, Nicoletta Pedemonte, Luis J. V. Galietta
-
Publication number: 20100130571Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound.Type: ApplicationFiled: November 19, 2009Publication date: May 27, 2010Applicant: The Regents of the University of CaliforniaInventors: Alan Verkman, Tonghui Ma
-
Patent number: 7696244Abstract: The invention provides compositions, including pharmaceutical preparations, which comprise one or more substituted thiophene, benzofuran, pyrimidinetrione, dihydropyridine, tetrahydrocarbazol or anthraquinone compounds. The invention also features methods of use of such compositions in increasing activity of mutant-cystic fibrosis transmembrane conductance regulator protein in a cell, e.g. by increasing ion transport in a mutant-CFTR.Type: GrantFiled: May 14, 2004Date of Patent: April 13, 2010Assignee: The Regents of the University of CaliforniaInventors: Alan Verkman, Luis J. V. Galietta, R. Kiplin Guy
-
Patent number: 7638543Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound.Type: GrantFiled: June 11, 2007Date of Patent: December 29, 2009Assignee: The Regents of the University of CaliforniaInventors: Alan Verkman, Tonghui Ma
-
Publication number: 20090048207Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound.Type: ApplicationFiled: July 18, 2008Publication date: February 19, 2009Applicant: The Regents of the University of CaliforniaInventors: Alan Verkman, Nitin Dattatraya Sonawane, Chatchai Muanprasat
-
Publication number: 20080318984Abstract: The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ?F508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquino-line-containing compounds of the invention, or an analog or derivative thereof.Type: ApplicationFiled: March 8, 2006Publication date: December 25, 2008Inventors: Alan Verkman, Nicoletta Pedemonte, Luis J.V. Galietta
-
Publication number: 20080319008Abstract: The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., ?F508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.Type: ApplicationFiled: June 2, 2005Publication date: December 25, 2008Inventors: Alan Verkman, R.Kiplin Guy, Nicoletta Pedemonte, Luis J.V. Galietta
-
Publication number: 20080311041Abstract: The invention provides chromoionophore compounds comprising a triazacryptand (TAC) K+ ionophore conjugated to at least a first chromophoric moiety (e.g., xanthylium dyes and derivatives thereof). In related embodiments, the chromoionophore compounds further comprise a second chromophoric moiety which is insensitive to potassium binding by the TAC ionophore, thus providing for dual wavelength detection and absolute determination of K+ concentration. The invention further provides methods and kits for the determination of K+ concentrations in biological systems, either in vitro or in vivo, using embodiments of inventive chromoionophores.Type: ApplicationFiled: October 11, 2006Publication date: December 18, 2008Inventors: Alan Verkman, Prashant A. Padmawar
-
Publication number: 20080221120Abstract: The invention provides compositions, pharmaceutical preparations, and methods for modulating angiogenesis and/or cell migration in a subject having a cellular proliferative disease (e.g., cancer), or a disease or condition amenable to treatment by enhancing cellular proliferation and cell migration (e.g., angiogenesis), by modulating the activity of an aquaporin, such as aquaporin-1. The compositions and pharmaceutical preparations of the invention may comprise one or more of compounds that modulate the activity of aquaporin-1.Type: ApplicationFiled: March 21, 2006Publication date: September 11, 2008Inventor: Alan Verkman
-
Patent number: 7414037Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound.Type: GrantFiled: March 29, 2005Date of Patent: August 19, 2008Assignee: The Regents of the University of CaliforniaInventors: Alan Verkman, Nitin Dattatraya Sonawane, Chatchai Muanprasat
-
Publication number: 20080064666Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound.Type: ApplicationFiled: June 11, 2007Publication date: March 13, 2008Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Alan Verkman, Tonghui Ma
-
Publication number: 20070265316Abstract: The invention provides compositions, pharmaceutical preparations and methods for activation of the ?F508 cystic fibrosis transmembrane conductance regulator protein (?F508 CFTR) that are useful for the treatment and study of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more tetrahydrobenzothiophene, benzofuran, pyramidinetrione, dihydropyridine, tetraahydrocarbazol or anthraquinone compounds (referred to as “activator compounds”). The invention provides methods increasing ion transport in a ?F508 CFTR in a cell by contacting the cell with an effective amount of an activator compound. In other embodiments, the invention also provides a method of treating a patient suffering from a ?F508 CFTR-mediated disease or condition, for example CF, by administering to the patient an efficacious amount of an activator compound. Kits for use in the subject methods are also provided.Type: ApplicationFiled: May 14, 2004Publication date: November 15, 2007Inventors: Alan Verkman, Luis Galietta, R. Guy
-
Patent number: 7235573Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for treating secretory diarrhea. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients, and/or diluents.Type: GrantFiled: September 30, 2003Date of Patent: June 26, 2007Assignee: The Regents of the University of CaliforniaInventors: Alan Verkman, Tonghui Ma
-
Publication number: 20050239740Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound.Type: ApplicationFiled: March 29, 2005Publication date: October 27, 2005Inventors: Alan Verkman, Nitin Sonawane, Chatchai Muanprasat